Creative Planning Vaxart, Inc. Transaction History

Creative Planning

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 21, 2023	SELL	$0.6 - $1.41 $150 - $352	-250 Reduced 0.51%	48,500 $35,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $532 - $937	-750 Reduced 1.52%	48,750 $37,000
Q4 2022 Feb 10, 2023	BUY	$0.75 - $2.24 $15,749 - $47,037	20,999 Added 73.68%	49,500 $47,000
Q3 2022 Nov 03, 2022	BUY	$2.09 - $4.5 $2 - $4	1 Added 0.0%	28,501 $62,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $5.28 $2,700 - $5,280	1,000 Added 3.64%	28,500 $100,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $24,453 - $37,848	5,700 Added 26.15%	27,500 $139,000
Q4 2021 Feb 11, 2022	BUY	$5.77 - $7.96 $59,956 - $82,712	10,391 Added 91.08%	21,800 $137,000
Q3 2021 Nov 10, 2021	BUY	$6.67 - $9.8 $76,098 - $111,808	11,409 New	11,409 $91,000
Q1 2021 Apr 30, 2021	SELL	$5.64 - $23.33 $62,604 - $258,962	-11,100 Closed	0 $0
Q4 2020 Jan 29, 2021	SELL	$3.5 - $7.98 $8,540 - $19,471	-2,440 Reduced 18.02%	11,100 $63,000
Q3 2020 Nov 05, 2020	BUY	$4.78 - $16.97 $64,721 - $229,773	13,540 New	13,540 $90,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.